Godlewska Beata R, Olajossy-Hilkesberger Luiza, Marmurowska-Michałowska Halina, Olajossy Marcin, Landowski Jerzy
Klinika Chorób Psychicznych i Zaburzeń Nerwicowych AM w Gdańisku.
Psychiatr Pol. 2006 Sep-Oct;40(5):995-1007.
Introduction of a new group of antipsychotic drugs, called atypical because of the proprieties differing them from classical neuroleptics, gave hope for the beginning of a new era in treatment of psychoses, including schizophrenia. Different mechanisms of action not only resulted in a broader spectrum of action and high efficacy but also in a relative lack of extrapiramidal symptoms. However, atypical neuroleptics are not totally free from adverse effects. Symptoms such as sedation, metabolic changes and weight gain, often very quick and severe - present also in the case of classical drugs, but put to the background by extrapiramidal symptoms--have become prominent. Weight gain is important both from the clinical and subjective point of view--as associated with serious somatic consequences and as a source of enormous mental distress. These problems are addressed in this review, with the focus on weight gain associated with the use of specific atypical neuroleptics.
一类新型抗精神病药物的出现带来了希望，有望开启包括精神分裂症在内的精神病治疗的新时代。这类药物被称为非典型抗精神病药物，因其特性与经典抗精神病药物不同。不同的作用机制不仅带来了更广泛的作用谱和更高的疗效，还相对减少了锥体外系症状。然而，非典型抗精神病药物并非完全没有不良反应。诸如镇静、代谢变化和体重增加等症状，这些症状在经典药物中也会出现，而且往往迅速且严重，但之前被锥体外系症状掩盖，现在却变得突出。体重增加从临床和主观角度来看都很重要，它既会带来严重的躯体后果，也是巨大精神痛苦的来源。本综述将探讨这些问题，重点关注使用特定非典型抗精神病药物导致的体重增加。
